



EGM Analysis - 2025

9 February 2026

Banca Profilo Research Team

Francesca R. Sabatini - Head of Equity Research

Enrico Luca, CFA - Equity Research Analyst

Michele Calusa - Equity Research Analyst



Agenda



EGM ALL COMPANIES



2025 NEW LISTINGS



EGM

2025 YTD – EGM Highlights

Euronext Growth Milan is dedicated to dynamic and competitive listed SMEs seeking capital to finance growth through a balanced regulatory approach. Euronext Growth Milan offers a simplified path to listing, compared to the Euronext Milan, with minimum access requirements and fulfilments tailored to SMEs.

- **Delistings continue.** Despite 2025 ultimately closed with 21 IPOs and 19 delistings, preserving a marginally positive net balance, it marks a clear worsening versus both 2024 and historical trends.
- **EGM remains the leading public channel for equity raising.** EGM dominated the IPO activity in 2025, primarily through capital increases. During 2025 there were 21 IPOs on EGM vs zero on other segments of Borsa Italiana.
- **A notable reversal in market size** after a prolonged downward trend. EGM's market capitalization reached €10.6bn at end-December 2025 (vs. €9.4bn at YE24).
- **Limited number of «Gems».** Only 3 companies meet quality thresholds for size, profitability and free float to be considered true «gems» of the market.
- **M&A Hub.** The EGM remains vibrant for corporate transactions, with 118 deals in 2025.
- **Liquidity shows early signs of improvement.** In 2025, average trading volumes surged to €171mln, with an acceleration in 4Q25 at €617.6mln (+24% qoq).
- **FNSI launch.** The Fondo Nazionale Strategico Indiretto has been introduced as a public-private investment vehicle to support SMEs. Initial commitments have already come from four Italian asset managers.
- **Index performance, trend inversion.** The FTSE Italia Growth index has inverted the previous two-year negative trend. It rebounded 20% from the fall in April and reported +9% yoy in 2025 (vs -5.2% in FY24, vs -10.9% in FY23).

FNSI Presentation

On January 23rd, a presentation of the Fondo Strategico Nazionale Indiretto was held at Borsa Italiana, featuring representative from CdP, MEF, FNSI, asset managers and institutional investors.

According to FNSI, the potential amount of resources that could be mobilized by the end of 2027 ranges from €800mln (8 funds) to €1.6bn (10/12 funds).

Key takeaways

- In 1H25, the **Fondo Nazionale Strategico Indiretto**, promoted by the Ministry of Economy and Finance (MEF) and managed by CDP, was **launched**. The initial endowment amounts to €350 million, with up to 49% of public resources allocated to investment funds (OICR) mandated to invest at least 70% in Italian equity securities issued by **small- and mid-cap non-financial companies**, not included in the FTSE MIB, for a minimum period of five years.
- Most **major Italian asset managers** have **joined** the initiative, attracting interest also from **pension funds**. 13 managers applied; 8 obtained authorization from the Supervisory Authority, and 4 have already been subscribed by CDP. CDP's Board extended the approval, activation, fundraising, and investment timeline to 1H27, to avoid conditions of excessive market demand.
- As of the date of the presentation, the four CDP-approved funds had raised a total of €400 million, with the FNSI contributing approximately 43%. Expected fundraising per fund ranges between €50-100 million, while the FNSI may subscribe €35-50 million in each OICR.
- Additional rules include:
 - ✓ A single investment may not exceed 10% of the OICR's total assets.
 - ✓ The top five holdings may not exceed 40% of the portfolio.
 - ✓ An OICR may not hold more than 10% of a company's share capital, nor more than 5% of an IPO offering.
 - ✓ IPO primary offers must amount to at least €10 million. If smaller, the OICR may invest 12 months after the IPO, provided that the company had a free float of at least 20% and a market capitalization of at least €50 million within the 45 days preceding the investment.

The **Government** is also considering **additional measures** to stimulate investor interest in smaller-capitalization companies. These may include tax incentives to reward long-term investor commitment and the establishment of a Foundation dedicated to funding equity research for smaller companies.



A structural decline in EGM appeal




After a still-positive balance in 2024 (21 listings vs. 11 delistings), market dynamics have **worsened in 2025**, which at one point saw delistings overtake new listings. While the year ultimately closed with **21 IPOs and 19 delistings**, preserving a marginally positive net balance, this outcome marks a clear worsening versus both 2024 and historical trends.

Low valuations, limited liquidity and rising compliance costs have been pushing more companies to go private, sustaining M&A momentum: after 16 OPAs in 2023-24, the trend has continued into 2025, with 11 successful transactions.



IPO, delisting and net change of companies in EGM

Source: Consob, Euronext



Tender offers

Nevertheless, EGM remains the **leading public channel for equity raising in Italy**: there have been 21 new listings (20 via *Private Placement*, worth €128mln with an avg. of €6.1mln, and 1 *Direct Listing*), compared to **zero IPOs on other segments** of Borsa Italiana.


On the listing side, **Banca Profilo remains active**, having brought Braga Moro, ETS and Markbass to market in 2025, raising a total of €12.8mln.

EGM's market size grows




EGM's market size shows a notable reversal after a prolonged downward trend: total **market capitalization reached €10.6bn** at end-December (vs. €9.4bn at YE24), with average market cap increasing to €53.4mln (vs. €45.8mln at YE24). However, this market remains dominated by small caps: **89%** of companies are **below €100mln** (88% at YE24) and 57% below €25mln of market cap (55% at YE24).

In 2025, 21 IPOs were completed with **only 4 deals above €10mln**. Although average proceeds (€6.1mln) remain below the €8mln recorded in 2024, the narrowing gap between average and median €5mln in 2025 vs. a €3.7mln median in 2024, indicates a **healthier distribution of deal sizes** and a broader, more structural improvement in market attractiveness.



EGM segment by market capitalization

Source: Bloomberg, Euronext




EGM IPOs count and raised proceeds


Limited number of “Gems”



Although the size of the EGM has been increasing, there are **still few, far too few, companies which meet quality thresholds** for size, profitability and free float to be considered true «gems» of the market. Only 3 companies in the EGM show €100mln in revenue or market capitalization, more than 10% EBITDA margin (with positive Net income), and at least 30% free float.



Only 3 companies simultaneously meet common investment requirements




Capitalization, Sales, EBITDA Margin (FY24) and Free Float of the 3 companies that meet our requisites

Best companies in terms of size, profitability and liquidity




At the end of December,


- only 38 companies generated above €100mln FY24 revenue or market cap (20% of total)
- 91 had a FY24 EBITDA margin >10% and positive Net Income (44% of total), including two of our coverage names (DEA and Arterra Bioscience)
- 59 have free float higher than 30% (28% of total)



Top 10 companies by Market Cap



Top 10 Companies by FY24 EBITDA margin



Top 10 Companies by free float

Source: Bloomberg


Blue circles indicate companies under our coverage



Over the past five years, **M&A activity among EGM companies has grown steadily.**

Momentum has continued into 2025, setting **new first- and third-quarter records** with 25 and 29 deals, respectively, reaching a total of **118 transactions**.

This sustained trend confirms EGM as one of the most dynamic segments of the Italian market, with growth increasingly driven by strategic acquisitions.






of M&A transactions in EGM since 2020

Liquidity: early signs of improvement



In 2025, the **avg. monthly turnover was €171mln**. Liquidity in the segment, long a key weakness, is showing **early signs of improvement**. In 2025, **64% of companies traded less than 0.1% of their market cap**, compared with 74% in 2024, while over the last 3-months the average daily traded value rose to €57.1k from €52k in our latest report.

In 4Q25 **turnover spiked** to €617.6mln (+24% qoq) despite the absence of exceptional catalysts in global markets, potentially due to expectations of future inflows from the Fondo Nazionale Strategico Indiretto (FNSI).




FTSE ITALIA GROWTH index entered an upward trend



After reaching a **record high** of 11,551 in **January 2022**, the **FTSE Italia Growth Index** experienced a **liquidity crisis, bottoming out** at 7,594 in late **October 2023**.

Since then, it has **partially recovered** and **recently stabilized** around 8,500 points for: (i) undemanding valuations; (ii) the ECB easing monetary policy; and (iii) optimism regarding new specific stimulus measures activated in 1H25.

In early **2025**, the EGM hit a new low of 7,300 points in April but quickly rebounded, along with global equity markets, following the U.S. Administration's announcement and subsequent suspension of tariffs. After this brief, externally driven disruption, **the EGM has rallied** almost more than **20%** peaking at 8,853 and slightly declining at 8,615 at the end of the year but still **+9% yoy** (vs -5.2% in FY24, vs -10.9% in FY23).





FTSE ITALIA GROWTH index overperforming European peers



The **FTSE Italia Growth Index** has not only outperformed the **Euronext Growth All Shares Index** over the past three years (-7.7% vs -13.9%, respectively), but it has also demonstrated relative strength since November 2023 (+11.4% vs +2.6%). After both indices bottomed around the same time, a divergence emerged. Performance in the last 12M was broadly in line across the two indices.

This overperformance is partly attributable to the **generally lower valuations of EGM companies**, which continue to attract foreign savings, significantly present even during recent new listings.

In fact, over the past three years, the **FTSE Italia Growth** has shown a slightly **lower median EV/Sales** ratio compared to the Euronext Growth All-Share, although its recent performance has contributed to a gradual narrowing of the valuation gap.



The Euronext Growth All Shares is a full market capitalization based index consisting of companies listed on the Euronext Growth markets (Italy, France, Belgium, Ireland, Norway).

Source: Bloomberg


EV/Sales FTSE Italia Growth and Euronext Growth All-Share

EGM - Growth and profitability 1H25 vs FY24




In 1H25, **58%** of EGM companies reported **positive yoy revenue growth** (slightly below 62% in FY24), while the **average revenue growth was 8%**, down from 10% in FY24.

On the profitability side, **38%** of companies achieved an **EBITDA margin above 15%** (vs. 42% in FY24), confirming the segment's solid earnings potential.



YoY revenue growth in EGM*




EBITDA margin in EGM*




In January, consensus estimates for 2025E and 2026E Revenues were revised slightly upward compared to our last report in November. **Revenue** is now expected at €66.6mln in 2025 (+18% yoy) and €75.2mln in 2026 (+17% yoy), versus previous estimates of €62.7mln and €70.9mln. **EBITDA** is projected at €9.1mln in 2025 and €11.7mln in 2026, with average **margin**s improving to 14.5% and 16.8%, broadly unchanged compared to previous consensus.

Lack of changes in marginality should be expected as there are no major releases after November, while the change in Revenues is likely due to some outliers.



EGM* consensus revenue



EGM* consensus EBITDA


EGM - Sectors market multiples 1-year trend



In the last 12 months, the **median EGM EV/EBITDA 1-year forward increased** from 5x to 7x.

Basic Materials saw **the largest 12M re-rating, from 4.2x to 7x**, similarly Consumer Discretionary was up from 5.2x to 8x

The only sector that saw a **de-rating** was Utilities down from 6.5x to 4.6x.




EGM - Sector market multiples



As of end-2025, the EGM segment shows a median **EV/EBITDA 2026E of 5x**, up from 5.3x at end-October.

Compared to our previous report, Basic Materials became the second most expensive surpassing both Health Care and Technology due to their de-rating.

Among sectors, **Energy** remains **the cheapest**, while **Consumer Staples** continues to be **the most expensive** while also seeing the **largest re-rating at +0.9x**. Healthcare saw the sharpest de-rating over the period.



Median EV/EBITDA FY26 by sector



Agenda



EGM ALL COMPANIES



2025 NEW LISTINGS


EGM – Focus on new listings




In 2025, **21 IPOs** were completed (20 via *Private Placement*, raising €87.4mln, and 1 *Direct Listing*). After a slow first half with only 6 IPOs, activity accelerated with 10 listings in 3Q25 and 5 in 4Q25. Sector-wise, the IPOs were diversified, with **Industrials** leading at **7 listings**, followed by **Consumer Discretionary** with 5.

Three IPOs were managed by Banca Profilo: 2 *Industrials* (Bragamoro and ETS) and 1 *Consumer Discretionary* (Markbass).

The **median market cap** of newly listed companies stands at **€25mln** (vs. an average of €28mln). At the end of 2025, **post-IPO returns shows wide dispersion**, from -48% for Comtel to +111% for Metriks Ai, with an average of 20.9%, skewed above the median of 3.7% due to strong positive outliers.




2025 New Listings by Sector



2025 New Listings by Market Capitalization

Source: Bloomberg
Blue circles indicate companies under our coverage




Performance since IPO

EGM - New listings by revenue and margin




The 2024 figures illustrate the size and profitability profile of companies that went public in 2025, excluding the SPAC Friends. **Sales** range from 0 for Gain360 to €181.3mln for Haiki Cobat, with **most companies below €50mln**.

EBITDA margins are highly dispersed, from 2% for RT&L to 29% for ETS, reflecting diverse business models and cost structures. Median sales in the sample are around €16.4mln and median EBITDA margin is approximately 15%.



2025 IPOs by FY24 sales

Source: Bloomberg
Blue circles indicate companies under our coverage



2025 IPOs by 2024 EBITDA and EBITDA margin



References



Via Cerva 28
20122 Milano
Tel. +39 02 58408
www.bancaprofilo.it

Francesca Sabatini
Head of Equity Research

francesca.sabatini@bancaprofilo.it
Tel. +39 02 58408.461

Enrico Luca, CFA
Equity Research Analyst

enrico.luca@bancaprofilo.it
Tel. +39 02 58408.752

Michele Calusa
Equity Research Analyst

michele.calusa@bancaprofilo.it
Tel. +39 02 58408.784

Report written on 09/02/2026 at 15:00

Disclaimer



ANALYST'S AND BANK'S INFORMATION

THIS DOCUMENT HAS BEEN DRAFTED BY FRANCESCA SABATINI WHO IS EMPLOYED BY BANCA PROFILO S.P.A. ("THE BANK") AS FINANCIAL ANALYST; FRANCESCA SABATINI IS RESPONSIBLE FOR THE DRAFTING OF THE DOCUMENT. BANCA PROFILO S.P.A. IS A BANK AUTHORISED TO PERFORM BANKING AND INVESTMENT SERVICES; IT IS PART OF BANCA PROFILO BANKING GROUP (THE "GROUP") AND IT IS SUBJECT TO THE MANAGEMENT AND CO-ORDINATION OF AREPO BP S.P.A. (THE "PARENT COMPANY"). SATOR PRIVATE EQUITY FUND "A" LP (THE "PARENT ENTITY") HOLDS INDIRECT CONTROL PARTICIPATION INTERESTS IN BANCA PROFILO.

THE BANK IS REGISTERED WITH THE ITALIAN BANKING ASSOCIATION CODE NO. 3025 AND IS SUBJECT TO THE REGULATION AND SURVEILLANCE OF THE BANK OF ITALY AND OF CONSOB (COMMISSIONE NAZIONALE PER LE SOCIETÀ E LE BORSA). THE BANK HAS PREPARED THIS DOCUMENT FOR ITS PROFESSIONAL CLIENTS ONLY, PURSUANT TO DIRECTIVE 2004/39/EC AND ANNEX 3 OF THE CONSOB REGULATION ON INTERMEDIARIES (RESOLUTION N. 16190). THIS DOCUMENT IS BEING DISTRIBUTED AS OF [JUNE THE 6th 12:00].

THE ANALYST FRANCESCA SABATINI WHO HAS DRAFTED THIS DOCUMENT HAS SIGNIFICANT EXPERIENCE IN BANCA PROFILO S.P.A. AND OTHER INVESTMENT COMPANIES. THE ANALYST AND ITS RELATIVES DO NOT OWN FINANCIAL INSTRUMENTS ISSUED BY THE ISSUER AND SHE DOES NOT ACT AS SENIOR MANAGER, DIRECTOR OR ADVISOR FOR THE ISSUER. THE ANALYST DOES NOT RECEIVE BONUSES, INCOME OR ANY OTHER REMUNERATION CORRELATING, DIRECTLY OR INDIRECTLY, TO THE SUCCESS OF THE INVESTMENT BANKING OPERATIONS OF BANCA PROFILO S.P.A.

A REDACTED VERSION OF THIS REPORT HAS BEEN DISCLOSED TO THE ISSUER TO PERMIT IT TO REVIEW AND COMMENT ON FACTUAL INFORMATION RELATING TO THE ISSUER AND THIS REPORT HAS BEEN AMENDED FOLLOWING SUCH DISCLOSURE PRIOR TO ITS FINAL DISSEMINATION.

THIS DOCUMENT IS BASED UPON INFORMATION THAT WE CONSIDER RELIABLE, BUT THE BANK HAS NOT INDEPENDENTLY VERIFIED THE CONTENTS HEREOF. THE OPINIONS, ESTIMATES AND PROJECTIONS EXPRESSED IN IT ARE AS OF THE DATE HEREOF AND ARE SUBJECT TO CHANGE WITHOUT NOTICE TO THE RECIPIENT. PAST PERFORMANCE IS NOT GUARANTEE OF FUTURE RESULTS.

THIS REPORT HAS BEEN PREPARED BY ITS AUTHORS INDEPENDENTLY OF THE COMPANY AND ITS SHAREHOLDERS, SUBSIDIARIES AND AFFILIATES. THE BANK HAS NO AUTHORITY WHATSOEVER TO GIVE ANY INFORMATION OR MAKE ANY REPRESENTATION OR WARRANTY ON BEHALF OF THE COMPANY, ANY OTHER PERSON IN CONNECTION THEREWITHE. IN PARTICULAR, THE OPINIONS, ESTIMATES AND PROJECTIONS EXPRESSED IN IT ARE ENTIRELY THOSE OF THE AUTHOR HEREOF.

NO REPRESENTATION OR WARRANTY, EXPRESS OR IMPLIED, IS MADE AS TO AND NO RELIANCE SHOULD BE PLACED ON THE FAIRNESS, ACCURACY, COMPLETENESS OR REASONABLENESS OF THE INFORMATION, OPINIONS AND PROJECTIONS CONTAINED IN THIS DOCUMENT, AND NONE OF THE BANK, THE COMPANY, NOR ANY OTHER PERSON ACCEPTS ANY LIABILITY WHATSOEVER FOR ANY LOSS HOWSOEVER ARISING FROM ANY USE OF THIS DOCUMENT OR ITS CONTENTS OR OTHERWISE ARISING IN CONNECTION THEREWITHE.

NO DUPLICATION

NO PART OF THE CONTENT OF THE DOCUMENT MAY BE COPIED, FORWARDED OR DUPLICATED IN ANY FORM OR BY ANY MEANS WITHOUT THE PRIOR CONSENT OF THE BANK. BY ACCEPTING THIS REPORT, YOU AGREE TO BE BOUND BY THE FOREGOING LIMITATIONS.

NO OFFER OR SOLICITATION

THIS DOCUMENT DOES NOT CONSTITUTE AN OFFER OR INVITATION OR FORM PART OF AN OFFER, SOLICITATION OR INVITATION TO PURCHASE ANY SECURITIES, AND NEITHER THIS DOCUMENT NOR ANYTHING CONTAINED HEREIN SHALL FORM THE BASIS OF ANY CONTRACT OR COMMITMENT WHATSOEVER.

RECIPIENTS

THIS DOCUMENT IS GIVEN TO YOU SOLELY FOR YOUR INFORMATION ON A CONFIDENTIAL BASIS AND MAY NOT BE REPRODUCED OR REDISTRIBUTED, IN WHOLE OR IN PART, TO ANY OTHER PERSON. IN PARTICULAR, NEITHER THIS DOCUMENT NOR ANY COPY HEREOF MAY BE TAKEN OR TRANSMITTED IN OR INTO THE UNITED STATES (THE "U.S."), AUSTRALIA, CANADA OR JAPAN OR REDISTRIBUTED, DIRECTLY OR INDIRECTLY, IN THE U.S., AUSTRALIA, CANADA OR JAPAN. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S., AUSTRALIAN, CANADIAN OR JAPANESE SECURITIES LAWS.

THIS DOCUMENT IS BEING DISTRIBUTED ONLY TO, AND IS DIRECTED ONLY AT, PERSONS WHO ARE QUALIFIED INVESTORS WITHIN THE MEANING OF ARTICLE 2(1) (E) OF THE PROSPECTUS DIRECTIVE (DIRECTIVE 2003/71/EC) (ALL SUCH PERSONS BEING REFERRED TO AS "RELEVANT PERSONS"). THIS DOCUMENT MUST NOT BE ACTED ON OR RELIED ON BY PERSONS WHO ARE NOT RELEVANT PERSONS. ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS COMMUNICATION RELATES IS AVAILABLE ONLY TO RELEVANT PERSONS AND WILL BE ENGAGED IN ONLY WITH RELEVANT PERSONS.

IN CASE THAT THIS DOCUMENT IS DISTRIBUTED IN ITALY IT SHALL BE DIRECTED ONLY AT QUALIFIED INVESTORS WITHIN THE MEANING OF ARTICLE 100(1) (A) OF LEGISLATIVE DECREE NO. 58 OF FEBRUARY 24, 1998, AS AMENDED, AND ARTICLE 34-TER, PARA. 1, LETT B), OF CONSOB REGULATION NO. 11971 OF 1999, AS AMENDED. THIS DOCUMENT IS NOT ADDRESSED TO ANY MEMBER OF THE GENERAL PUBLIC IN ITALY. IN NO CIRCUMSTANCES SHOULD THIS DOCUMENT CIRCULATE AMONG OR BE DISTRIBUTED TO (I) A MEMBER OF THE GENERAL PUBLIC, (II) INDIVIDUALS OR ENTITIES FALLING OUTSIDE THE DEFINITION OF "QUALIFIED INVESTORS" AS SPECIFIED ABOVE OR (III) TO DISTRIBUTION CHANNELS THROUGH WHICH INFORMATION IS OR IS LIKELY TO BECOME AVAILABLE TO A LARGE NUMBER OF PERSONS.

THE DISTRIBUTION OF THIS DOCUMENT IN OTHER JURISDICTIONS MAY BE RESTRICTED BY LAW AND PERSONS INTO WHOSE POSSESSION THIS DOCUMENT COMES SHOULD INFORM THEMSELVES ABOUT, AND OBSERVE, ANY SUCH RESTRICTION. ANY FAILURE TO COMPLY WITH THESE RESTRICTIONS MAY CONSTITUTE A VIOLATION OF THE LAWS OF ANY SUCH OTHER JURISDICTION.

CONFLICTS OF INTEREST

THE BANK MAY, FROM TIME TO TIME, DEAL IN, HOLD OR ACT AS MARKET MAKER OR ADVISER, BROKER OR BANKER IN RELATION TO THE FINANCIAL INSTRUMENTS, OR DERIVATIVES THEREOF, OF PERSONS, FIRMS OR ENTITIES MENTIONED IN THIS DOCUMENT, OR BE REPRESENTED IN THE GOVERNING BODIES OF THE COMPANY. IN FACT, THE BANK ACTED AS GLOBAL COORDINATOR IN THE IPO OF THE ISSUER, BANCA PROFILO S.P.A. HAS ADOPTED INTERNAL PROCEDURES FOR THE PREVENTION AND AVOIDANCE OF CONFLICTS OF INTEREST WITH RESPECT TO THE RECOMMENDATIONS, WHICH CAN BE CONSULTED ON THE RELEVANT SECTION OF ITS WEBSITE (WWW.BANCAPROFILO.IT, IN THE SECTION "CLIENTI AZIENDALI E ISTITUZIONALI/ANALISI E RICERCA").

EQUITY RESEARCH PUBLICATIONS IN LAST 12M

THE BANK PUBLISHES ON ITS WEBSITE WWW.BANCAPROFILO.IT, ON A QUARTERLY BASIS, THE PROPORTION OF ALL RECOMMENDATIONS THAT ARE 'BUY', 'HOLD', 'SELL' OR EQUIVALENT TERMS OVER THE PREVIOUS 12 MONTHS, AND THE PROPORTION OF ISSUERS CORRESPONDING TO EACH OF THOSE CATEGORIES TO WHICH SUCH PERSON HAS SUPPLIED MATERIAL SERVICES OF INVESTMENT FIRMS SET OUT IN SECTIONS A AND B OF ANNEX 1 TO DIRECTIVE 2014/65/EU OVER THE PREVIOUS 12 MONTHS.

ADDITIONAL INFORMATION

THE BANK PROVIDES ALL OTHER ADDITIONAL INFORMATION, ACCORDING TO ARTICLE 114, PARAGRAPH 8 OF LEGISLATIVE DECREE 58/98 ("FINANCIAL DECREE") AND COMMISSION DELEGATED REGULATION (EU) 2016/958 AS OF 9 MARCH 2016 (THE "COMMISSION REGULATION") ON THE RELEVANT SECTION OF ITS WEBSITE (WWW.BANCAPROFILO.IT, IN THE SECTION "CLIENTI AZIENDALI E ISTITUZIONALI/ANALISI E RICERCA